Miami Cardiac and Vascular Institute Grand Rounds: ATTR Cardiac Amyloidosis - Towards Earlier Diagnosis and Treatment
Transthyretin cardiac amyloidosis (ATTR-CA) demonstrates progressive, potentially fatal, and infiltrative cardiomyopathy caused by extracellular deposition of transthyretin-derived insoluble amyloid fibrils in the myocardium. Two distinct types of transthyretin (wild type or variant) become unstable, and misfolding forms aggregate, resulting in amyloid fibrils. ATTR-CA, which has previously been underrecognized and considered to be rare, has been increasingly recognized as a cause of heart failure with preserved ejection fraction among elderly persons. With the advanced technology, the diagnostic tools have been improving for cardiac amyloidosis. Recently, the efficacy of several disease-modifying agents focusing on the amyloidogenic process has been demonstrated. ATTR-CA has been changing from incurable to treatable. Nevertheless, there are still no prognostic improvements due to diagnostic delay or misdiagnosis because of phenotypic heterogeneity and co-morbidities. Thus, it is crucial for clinicians to be aware of this clinical entity for early diagnosis and proper treatment.
Join Dr. David Wolinsky, as he provides strategies to optimize treatment to improve patient outcomes.
|Live- Baptist Hospital 5MCVI|
Cardiologists, Interventional Cardiologists, Cardiothoracic Surgeons, Interventional Radiologists, Pulmonologists, Hematologists, General Internists, Primary Care Physicians, Intensivist, General Surgeons, Anesthesiologists, Emergency Medicine Physicians, Hospitalists, Radiation Technologists, Nurses and other interested healthcare providers.
- Recognize the myriad presentations of Transthyretin Cardiac Amyloidosis (ATTR-CA).
- Effectively implement referral processes to increase early detection of cardiac amyloid.
- Utilize TTcPYP imaging to diagnose ATTR-CA.
- Optimize treatment, including disease-modifying therapy, to improve outcomes.
David Wolinsky, M.D., FACC, MASNC
Section Head, Nuclear Cardiology
Director, Cardiac Amyloid Center
Cleveland Clinic Florida
David Wolinsky, M.D indicated that he is a consultant for Astellas and AKCEA, and he is a member of the Speakers’ Bureau for Astellas, AKCEA and Alnylam. He will not include off-label or unapproved product usage in his presentation or discussion.
James Benenati, M.D., indicated that he is a consultant for Penumbra and Bard. He is also a stock shareholder for Penumbra and Scientia. Barry Katzen, M.D. has indicated that he is a consultant for Boston Scientific, Phillips Medical, W.L. Gore and Bard. Dr. Theodore Feldman has indicated that he is a member of the Speakers’ Bureau for Regeneron, Sanofi, Boehringer Ingeldeim, and Novartis.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been approved for 1 credit hour, CE Broker Course #20-676407, by the Florida Boards of Medicine and Osteopathic Medicine and by the Florida Council of Physician Assistants.
This activity has also been approved for 1 credit hour for Nurse Practitioners and Nurses.. Baptist Health South Florida CE Broker Provider #50-182.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Florida Board of Nursing
- 1.00 Nurse Practitioners
- 1.00 Florida Bureau of Radiation Control
- 1.00 General certificate of attendance
Pre-registration is required. Please log in to register.
Technical Support: If you are experiencing technical difficulties or have received an error message, please send an email to CME@BaptistHealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours.